Atossa Therapeutics, Inc.Atossa Therapeutics, Inc.Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪169.16 M‬USD
−0.24USD
‪−30.09 M‬USD
‪125.25 M‬
Beta (1Y)
1.39

About Atossa Therapeutics, Inc.

CEO
Steven C. Quay
Headquarters
Seattle
Employees (FY)
12
Founded
2008
ISIN
US04962H5063
FIGI
BBG002NCD8C8
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ATOS is 1.41 USD — it has increased by 4.44% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Atossa Therapeutics, Inc. stocks are traded under the ticker ATOS.
Atossa Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
ATOS stock is 19.35% volatile and has beta coefficient of 1.39. Check out the list of the most volatile stocks — is Atossa Therapeutics, Inc. there?
One year price forecast for Atossa Therapeutics, Inc. has a max estimate of 4.00 USD and a min estimate of 4.00 USD.
ATOS earnings for the last quarter are −0.05 USD whereas the estimation was −0.07 USD which accounts for 25.00% surprise. Estimated earnings for the next quarter are −0.06 USD. See more details about Atossa Therapeutics, Inc. earnings.
Yes, you can track Atossa Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ATOS stock has fallen by 20.34% compared to the previous week, the month change is a 7.63% rise, over the last year Atossa Therapeutics, Inc. has showed a 85.53% increase.
ATOS net income for the last quarter is ‪−7.75 M‬ USD, while the quarter before that showed ‪−6.23 M‬ USD of net income which accounts for −24.48% change. Track more Atossa Therapeutics, Inc. financial stats to get the full picture.
Today Atossa Therapeutics, Inc. has the market capitalization of ‪169.16 M‬, it has decreased by 4.89% over the last week.
No, ATOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ATOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Atossa Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
ATOS reached its all-time high on Mar 19, 2013 with the price of 2231.78 USD, and its all-time low was 0.50 USD and was reached on Dec 28, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 12.00 employees. See our rating of the largest employees — is Atossa Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Atossa Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Atossa Therapeutics, Inc. stock shows the neutral signal. See more of Atossa Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Atossa Therapeutics, Inc. future price: according to them, ATOS price has a max estimate of 4.00 USD and a min estimate of 4.00 USD. Read a more detailed Atossa Therapeutics, Inc. forecast: see what analysts think of Atossa Therapeutics, Inc. and suggest that you do with its stocks.